A clinical trial conducted in Israel found that a fourth dose of the coronavirus vaccine provides only “limited defence”. This was reported on Monday the 17th of January 2022. and resulted in shares of several top COVID-19 vaccine pharma companies sinking by Tuesday morning.

Last month the Sheba Medical Center at Tel Hashomer, Israel, began administering a fourth dose of vaccine to more than 270 medical workers. All had previously been vaccinated three times already with the Pfizer gene therapy. 154 went on to receive the  Pfizer-BioNtech product and 120 others received Moderna (source)

Increase in Antibodies is “nice”

The Director of the hospital’s infection disease Epidemiology Unit at Sheba Medical Center, Professor Gili Regev-Yochay said on Monday that two weeks after receiving the Pfizer vaccine and one week after receiving the Moderna vaccine, “the increase in antibodies is nice” but not enough to stop infection.

The clinical trial found that both groups showed increases in antibodies “slightly higher” than they had following the third vaccine last year, but it was said the increased antibodies did not prevent the spread of that which is termed “omicron”.

Not Really a Booster

Professor Regev-Yochay said “What we saw with the third dose was that it was superior with respect to the second dose—much higher antibodies, much higher neutralization and the antibodies were not just higher in quantity but also in quality,”

She continued  “What we see now is an increase in the number [of antibodies] similar to what we saw after the third dose, meaning it is not really a booster”

Sheba online says that Israel with almost 60 percent of its population fully vaccinated continues to “lead the world’s fight against COVID-19 vaccinations per capita,” despite the vaccination campaign slowing down,

The vast majority of those unjabbed are children under 18 years old, however, the Israeli Health Ministry is expected to approve the vaccine for children aged 12 and over in the coming days, following approval by the FDA  “U.S. Food and Drug Administration”

No Need For Jab Mandates

Nevertheless, the experts have spoken and have said that Israel has reached herd immunity without vaccinating children. Prof. Regev-Yochay, added: “The recommendation at the moment is to vaccinate the youth, but anyone can take it on a personal level and decide for themselves, there is no need to mandate their vaccination.”

Meanwhile, Israeli Health Minister, Yuli Edelstein, recently announced that Israel will not extend most domestic COVID-19 restrictions as the infection rate remains low throughout the country.

Share Value Falls

After the report, in fact, the very next morning the shares in the vaccine stock had fallen with Pfizer BioNTech (NASDAQ:BNTX) being hit the hardest, with the stock down 9.8% and shares of Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) had fallen 7.4% and 8.2%, respectively.

According to an article in Nasdaq namely, Why BioNTech, Moderna, and Novavax Stocks Are Sinking …the stocks and shares experts blame the study on the fall of the pharma giants.

 The author of the article published on January the 18th, Keith Speights, says, “It’s easy to determine why BioNTech stock is dropping. Results from a clinical trial conducted in Israel found that a fourth dose of the COVID vaccine developed by BioNTech and its big partner, Pfizer (NYSE:PFE), didn’t prevent infection by the coronavirus omicron variant. 

However he was optimistic that there would be money to be made from shares in the future BioNTech (with Pfizer) and Moderna are also developing omicron-specific versions of their vaccines. The results from the latest Israeli study could simply mean that these new vaccines will have greater opportunities.

Although, it just goes to show that if the multitude of studies that have been conducted showing that not only are the vaccines ineffective but are also harmful, were reported on mainstream news channels, the big pharma companies would arguably not be making the vast profits that the have been and would likely stop producing the bioweapon.